Endocrinology

Help Shape the Future of Denosumab Treatment

As biosimilars enter the denosumab landscape, your perspective as a healthcare provider is critical in understanding what factors influence treatment decisions. This brief survey explores your views on reimbursement considerations, coding challenges, switching comfort, and drivers of biosimilar choice. As a thank you, by completing the survey, you’ll be entered into a drawing for a chance to win a $200 gift card.

Take the survey now and make your voice heard

Latest News

Model Predicts Complications of T2D and  Progression Based on Risk Factors
Mathematical Model Forecasts Diabetes Complications 15 Years Out, Confirms Legacy Effect of Early Control

October 30th 2025

The model predicts 14 different T2D complications that can develop over ~15 years, and models how the disease progresses by predicting change in risk factors over time.

Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial / image credit eking University People’s Hospital
Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial

October 28th 2025

AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial

October 27th 2025

Semaglutide Cardioprotective Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential  / image credit John Deanfield, CBE  Courtesy of University College London
Semaglutide CV Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential

October 23rd 2025

Early Natural Menopause Associated With Increased Metabolic Syndrome Risk, According to New Research
Early Natural Menopause Associated With Increased Metabolic Syndrome Risk, According to New Research

October 21st 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.